Lillian L. Siu

Lillian L. Siu

Auto-generated profile, based on publicly available information

Lillian L. Siu

Princess Margaret Cancer Centre, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2009 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CTChristophe Le Tourneau
Christophe Le Tourneau
JLJ. Jack Lee
J. Jack Lee
LSLillian L. Siu
Lillian L. Siu
Phase I clinical trials are an essential step in the development of anticancer drugs. The main goal of these studies is to establish the recommended dose and/or schedule of new drugs or drug combinations for phase II trials. The guiding principle for dose escalation in phase I trials is to avoid exposing too many patients to subtherapeutic doses while preserving safety and maintaining rapid accrual. Here we review dose escalation methods for phase I trials, including the rule-based and model-based dose escalation methods that have been developed to evaluate new anticancer agents. Toxicity has traditionally been the primary endpoint for phase I trials involving cytotoxic agents. However, with the emergence of molecularly targeted anticancer agents, potential alternative endpoints to delineate optimal biological activity, such as plasma drug concentration and target inhibition in tumor or surrogate tissues, have been proposed along with new trial designs. We also describe specific methods for drug combinations as well as methods that use a time-to-event endpoint or both toxicity and efficacy as endpoints. Finally, we present the advantages and drawbacks of the various dose escalation methods and discuss specific applications of the methods in developmental oncotherapeutics.

10 October 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
IDI Duran
I Duran
JKJ Kortmansky
J Kortmansky
DSD Singh
D Singh
HHH Hirte
H Hirte
WKW Kocha
W Kocha
LSL L Siu
L L Siu
Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety and pharmacodynamics of temsirolimus in patients with advanced neuroendocrine carcinoma (NEC). Thirty-seven patients with advanced progressive NEC received intravenous weekly doses of 25 mg of temsirolimus. Patients were evaluated for tumour response, time to progression (TTP), overall survival (OS) and adverse events (AE). Twenty-two archival specimens, as well as 13 paired tumour biopsies obtained pretreatment and after 2 weeks of temsirolimus were assessed for potential predictive and correlative markers. The intent-to-treat response rate was 5.6% (95% CI 0.6–18.7%), median TTP 6 months and 1-year OS rate 71.5%. The most frequent drug-related AE of all grades as percentage of patients were: fatigue (78%), hyperglycaemia (69%) and rash/desquamation (64%). Temsirolimus effectively inhibited the phosphorylation of S6 (P=0.02). Higher baseline levels of pmTOR (phosphorylated mammalian target of rapamycin) (P=0.01) predicted for a better response. Increases in pAKT (P=0.041) and decreases in pmTOR (P=0.048) after treatment were associated with an increased TTP. Temsirolimus appears to have little activity and does not warrant further single-agent evaluation in advanced NEC. Pharmacodynamic analysis revealed effective mTOR pathway downregulation.

15 April 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KYKaren W.L. Yee
Karen W.L. Yee
JPJoseph L. Pater
Joseph L. Pater
LPLam Pho
Lam Pho
BZBenny Chung-Ying Zee
Benny Chung-Ying Zee
LSLillian L. Siu
Lillian L. Siu
Purpose: To evaluate the enrollment of older patients (≥ 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States.

1 January 2003
Verified
Journal Article
Closed access
KCKelvin Chan
Kelvin Chan
AOAmit Oza
Amit Oza
LSLillian L Siu
Lillian L Siu

3 January 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LML Rhoda Molife
L Rhoda Molife
LYLi Yan
Li Yan
JVJoanna Vitfell-Rasmussen
Joanna Vitfell-Rasmussen
AZAdriane M Zernhelt
Adriane M Zernhelt
DSDaniel M Sullivan
Daniel M Sullivan
SMSusan Minton
Susan Minton
Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.

20 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
BTBen Tran
Ben Tran
JDJanet E. Dancey
Janet E. Dancey
SKSuzanne Kamel-Reid
Suzanne Kamel-Reid
JMJohn McPherson
John McPherson
PBPhilippe L. Bedard
Philippe L. Bedard
LSLillian L. Siu
Lillian L. Siu
In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital–University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.